BLOG

Healio

First patient enrolled in phase 1/2 study of hydroxyl dendrimer imaging agent

Ashvattha Therapeutics announced that the first patient has been enrolled in a phase 1/2 study to evaluate the ability of an imaging agent to cross the blood-brain barrier and target key markers of neuroinflammation.